Ardelyx (ARDX) shares soared 16% in the last trading session to close at 5.88.Themovewasbackedbysolidvolumewithfarmoreshareschanginghandsthaninanormalsession.Thiscomparestothestock′s2.9319 million in 2024, backed by growing demand for its two drugs, Ibsrela and Xphozah. Ibsrela sales in the fourth quarter of 2024 are expected to be $54 million, bringing the full ...